Navigation Links
WellWorld Science(R) Announces U.S. Launch of Livea(R),a Safe and Natural Appetite Control Supplement
Date:1/27/2010

LAS VEGAS, Jan. 27 /PRNewswire/ -- After more than 30 years of research and an extensive open-label weight loss study, WellWorld Science® announces the official U.S. launch of Livea®, a doctor-developed, non-prescription, patent-pending appetite-control supplement that is unlike any other dietary supplement on the market.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100127/NY44298 )

New research in neuropeptides has shown that certain people may have a medical issue causing an internal disconnect, which can lead to long-term health consequences that include obesity, heart disease and diabetes.  For a person living with this signaling defect, the normal digestive process that alerts the brain to stop eating may not work, leading these individuals to overeat until they have a feeling of being stuffed; and even then they may still feel the urge to eat.  Livea® mimics the body's natural signaling process making the body feel full, leading to weight loss.  And because the proprietary blend of ingredients is all-natural, it can be safely consumed for an extended period, unlike other products that can have long-term, adverse side effects after short-term use.

According to Joseph Fayad, M.D., FACP, FACG, a nationally-recognized gastroenterologist and leading expert at the forefront of neuropeptide research, "Based on an independent, open-label weight loss study, Livea® demonstrated that it safely and effectively helped patients consume fewer calories than those who did not take the supplement."  In fact, among the participants in this study, both men and women reported weight loss ranging between 18 and 59 pounds.(1)  Fayad continues, "These peptides, which Livea® activates, are being studied in their role in treating fatty liver disease, improving various organ functions and treating diverse autoimmune disorders, including Type II Diabetes and Multiple Sclerosis."

Weight loss study participants included Kai Hibbard, runner-up on the third season of The Biggest Loser®.  Kai has lost and kept off 67 pounds since starting the Livea® program as part of the open-label study in January 2009. According to Hibbard, now an AAFA-certified aerobics instructor, the hardest part about keeping the weight off after the show was combating the cravings following an "extreme diet."

"I would begin my day with the intention of eating healthy, but by the middle of the night when I was awake to feed my newborn, I was gorging on cookies," says Hibbard.  "The cravings had control over me, and I was feeling like a failure for not being able to maintain all the good habits I'd learned after being a part of the show."

Following her success, Kai joined the Livea® team as their spokesperson and is featured in their marketing program, including a series of two-minute commercial spots on cable, select regional broadcast markets and its website.  The spots also profile other participants who experienced amazing results as part of the study.

The positive results of Livea® and its Lifestyle Program go well beyond the weight loss benefits.  With current research showing a link between neuropeptide deficiency and many common health concerns, Livea® is not just leading the way in weight management but is breaking new ground for what may become the science of the future.

Livea®, manufactured in the USA, is now available online at www.Livea.com and in select doctor's offices and clinic outlets. To learn more about Livea®, visit www.Livea.com.

ABOUT WELLWORLD SCIENCE®

WellWorld Science® develops and distributes a series of non-pharmaceutical/nutraceutical products specifically targeted to improve consumers' general health, wellness, and well being. The Company's products, in general, target the ever-expanding global epidemic of the overweight condition and obesity. The Company's cornerstone product, Livea®, is a patent-pending appetite control product that has mass appeal to the millions of adults in the United States considered overweight or obese by virtue of solving the issue of portion control and the feeling of satiety. Livea® was developed and is distributed by WellWorld Science®. Livea® and WellWorld Science® are registered trademarks of WellWorld Science®. ©2009 WellWorld Science®. All rights reserved. FDA WARNING: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

(1) http://www.livea.com/docs/study.pdf

SOURCE WellWorld Science(R)

RELATED LINKS
http://www.livea.com

'/>"/>

SOURCE WellWorld Science(R)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)...  Xynomic Pharmaceuticals, Inc., an oncology drug research ... acquired exclusive worldwide rights to develop, manufacture and ... targeting hematological and solid tumors. To ... 2 clinical trials of Abexinostat in US, EU ... been completed, demonstrating that Abexinostat is clinically active ...
(Date:2/23/2017)... SEOUL , Südkorea, 23. Februar 2017 ... LED für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache ... kurzwellige ultraviolette Strahlung im Bereich zwischen 200 und 280 nm ... Ausbreitung von Bakterien, indem es ihre DNA zerstört. Das ... 280 nm. ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition ... has initiated a second print-run of its lavish luxury travel coffee table book. ... weighs in at more than six kilos, retails at EUR 1,000 per copy and ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis ... University of Pittsburgh points to eight genes that may explain why susceptibility to one ... the results of a study published today in the journal npj Schizophrenia. , ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is ... University predict that 47 percent of all jobs in the United States may be ... “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing to ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An Australian ... account of his paramedic experiences. Schanssema describes the tragedies he saw, as well as ... overcome them. , Schanssema, initially unsure of the career path he wanted to take, ...
Breaking Medicine News(10 mins):